Sino Biopharmaceutical Limited (FRA:SMZ1)
Germany flag Germany · Delayed Price · Currency is EUR
0.4416
+0.0104 (2.41%)
Last updated: Apr 25, 2025

Sino Biopharmaceutical Ratios and Metrics

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Apr '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Market Capitalization
8,0187,2447,39410,13511,54814,859
Upgrade
Market Cap Growth
-2.02%-2.02%-27.05%-12.23%-22.28%-4.98%
Upgrade
Enterprise Value
8,7438,0167,68810,82012,86915,405
Upgrade
Last Close Price
0.440.400.390.520.550.71
Upgrade
PE Ratio
17.3115.6424.8529.375.7142.82
Upgrade
PS Ratio
2.101.902.212.873.115.02
Upgrade
PB Ratio
1.421.281.521.972.215.29
Upgrade
P/TBV Ratio
2.101.891.962.592.847.22
Upgrade
P/FCF Ratio
--11.6014.8822.8430.42
Upgrade
P/OCF Ratio
--9.5511.9315.5522.28
Upgrade
EV/Sales Ratio
2.512.102.303.073.465.20
Upgrade
EV/EBITDA Ratio
12.099.929.4512.7517.0521.73
Upgrade
EV/EBIT Ratio
14.3411.7211.0814.8120.0730.02
Upgrade
EV/FCF Ratio
--12.0615.8825.4631.54
Upgrade
Debt / Equity Ratio
0.230.230.330.370.330.63
Upgrade
Debt / EBITDA Ratio
1.601.601.972.222.212.48
Upgrade
Debt / FCF Ratio
--2.542.813.363.64
Upgrade
Asset Turnover
0.450.450.410.420.500.56
Upgrade
Inventory Turnover
2.442.442.312.102.792.93
Upgrade
Quick Ratio
1.021.020.901.151.381.87
Upgrade
Current Ratio
1.261.261.051.291.532.08
Upgrade
Return on Equity (ROE)
11.82%11.82%12.12%11.94%55.25%20.20%
Upgrade
Return on Assets (ROA)
5.01%5.01%5.33%5.40%5.37%6.05%
Upgrade
Return on Capital (ROIC)
6.25%6.25%6.60%6.60%6.69%7.79%
Upgrade
Return on Capital Employed (ROCE)
11.30%11.30%13.30%12.30%10.30%11.30%
Upgrade
Earnings Yield
5.78%6.39%4.02%3.40%17.51%2.33%
Upgrade
FCF Yield
--8.62%6.72%4.38%3.29%
Upgrade
Dividend Yield
1.60%2.20%1.49%2.77%1.63%1.08%
Upgrade
Payout Ratio
--27.13%49.84%6.42%42.84%
Upgrade
Buyback Yield / Dilution
1.26%1.26%2.57%1.38%-2.57%0.06%
Upgrade
Total Shareholder Return
2.86%3.46%4.06%4.14%-0.94%1.14%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.